• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Alternate Dosing Regimens for Vismodegib: A Literature Review.

作者信息

Yang Kevin, Ho-Pham Hoang, Pieper Collin, Huang Conway C, Bergman Daniel J

机构信息

Department of Dermatology, University of Alabama at Birmingham, 510 20th St. S, FOT 858, 35233, Birmingham, AL, USA.

出版信息

Curr Treat Options Oncol. 2025 Jul;26(7):587-591. doi: 10.1007/s11864-025-01332-6. Epub 2025 May 26.

DOI:10.1007/s11864-025-01332-6
PMID:40418287
Abstract

Vismodegib is a hedgehog inhibitor used in the treatment of basal cell carcinomas and basal cell nevus syndrome. However, treatment is associated with significant side effects that can impact compliance, including fatigue, muscle cramps, hair loss, and taste disturbance. Multiple strategies to change dosing frequency have been implemented to improve the tolerability. Vismodegib may be administered with non-daily dosing or with drug holidays to improve the side effects associated with administration. Intermittent dosing of vismodegib may be more appropriate for patients with locally advanced BCC and drug holidays may be more suited for patients with basal cell nevus syndrome. The most appropriate strategy in each case though will ultimately depend on patient preference.

摘要

相似文献

1
Alternate Dosing Regimens for Vismodegib: A Literature Review.
Curr Treat Options Oncol. 2025 Jul;26(7):587-591. doi: 10.1007/s11864-025-01332-6. Epub 2025 May 26.
2
Hedgehog Pathway Inhibitor Therapy for Locally Advanced and Metastatic Basal Cell Carcinoma: A Systematic Review and Pooled Analysis of Interventional Studies.Hedgehog 通路抑制剂治疗局部晚期和转移性基底细胞癌:干预性研究的系统评价和汇总分析。
JAMA Dermatol. 2016 Jul 1;152(7):816-24. doi: 10.1001/jamadermatol.2016.0780.
3
Phase II, Single-Arm Trial of Induction and Concurrent Vismodegib With Curative-Intent Radiation Therapy for Locally Advanced, Unresectable Basal Cell Carcinoma.诱导治疗联合维莫德吉与根治性放疗治疗局部晚期不可切除基底细胞癌的 II 期单臂试验。
J Clin Oncol. 2024 Jul 1;42(19):2327-2335. doi: 10.1200/JCO.23.01708. Epub 2024 Apr 17.
4
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.抑制基底细胞痣综合征患者的 hedgehog 通路。
N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
5
Secondary cutaneous malignancy after treatment of basal cell carcinoma with hedgehog pathway inhibitor: a systematic review.治疗基底细胞癌的 Hedgehog 通路抑制剂后继发皮肤第二恶性肿瘤:系统评价。
Arch Dermatol Res. 2024 Oct 26;316(10):716. doi: 10.1007/s00403-024-03471-6.
6
Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial.在戈林综合征患者中局部应用刺猬蛋白抑制剂帕替吉布:一项II期试验。
Br J Dermatol. 2025 Mar 18;192(4):611-617. doi: 10.1093/bjd/ljae444.
7
Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.维莫德吉治疗基底细胞癌:ERIVANCE BCC试验的结果及意义
Future Oncol. 2014 May;10(6):927-36. doi: 10.2217/fon.14.50.
8
Remarkable Response to Vismodegib in a Locally Advanced Basal Cell Carcinoma on the Nose.
Cutis. 2025 May;115(5):E9-E11. doi: 10.12788/cutis.1228.
9
Prevalence of genetic alterations in basal cell carcinoma patients resistant to Hedgehog pathway inhibitors: a systematic review.对Hedgehog信号通路抑制剂耐药的基底细胞癌患者的基因改变患病率:一项系统评价
Ann Med. 2025 Dec;57(1):2516701. doi: 10.1080/07853890.2025.2516701. Epub 2025 Jun 16.
10
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.基底细胞痣综合征患者中 hedgehog 通路的抑制:多中心、随机、双盲、安慰剂对照、2 期临床试验的最终结果。
Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.